Perioperative Insulin Glargine Dosing Study

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The main objective of this study is to compare three strategies of evening insulin glargine dosing to preoperative glucose values in patients with diabetes undergoing surgery to determine which dosing strategies most often achieves the admission target study values of 100-179 mg/dl.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tamra Dukatz
• Collaborator: Sanofi
• Treatments: Insulin; Insulin Glargine; Insulin, Globin Zinc; Insulin, Short-Acting

Criteria

Inclusion Criteria:

• Scheduled for Surgical Procedure

• Self Management of Diabetes

• Currently on Evening Insulin Glargine prescribed by Primary Care Physician

• Age 18 or over

• Able to Communicate Clearly over the Phone

• Pre-screened by Anesthesia Department > 48 hours prior to Surgery

Exclusion Criteria:

• On Glucocorticoid Medication

• On Insulin Glargine Dual Dosing or Sliding Scale Regimen

• History of Hypoglycemia Unawareness

• Pregnancy or Lactating Female

• On Insulin Glargine for < 3 months